JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB52973

Anti-Aurora A antibody [EP1008Y]

5

(2 Reviews)

|

(28 Publications)

Rabbit Recombinant Monoclonal Aurora A antibody. Suitable for IHC-P, IP, WB and reacts with Human samples. Cited in 28 publications.

View Alternative Names

AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6, AURKA, Aurora kinase A, Aurora 2, Aurora/IPL1-related kinase 1, Breast tumor-amplified kinase, Ipl1- and aurora-related kinase 1, Serine/threonine-protein kinase 15, Serine/threonine-protein kinase 6, Serine/threonine-protein kinase Ayk1, Serine/threonine-protein kinase aurora-A, ARK-1, Aurora-related kinase 1

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora A antibody [EP1008Y] (AB52973)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Aurora A antibody [EP1008Y] (AB52973)

Formalin-fixed, paraffin-embedded human cervical carcinoma tissue stained for Aurora A with ab52973 (1/100 dilution) in immunohistochemical analysis. Inset panel is a larger magnification of the image.

Inset panel is a larger magnification of the image.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunoprecipitation - Anti-Aurora A antibody [EP1008Y] (AB52973)
  • IP

Lab

Immunoprecipitation - Anti-Aurora A antibody [EP1008Y] (AB52973)

Purified ab52973 at 1/50 dilution (2μg) immunoprecipitating Aurora A in HepG2 whole cell lysate.
Lane 1 (input) : HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab52973 + HepG2 whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab52973 in HepG2 whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 46 kDa

All lanes:

Immunoprecipitation - Anti-Aurora A antibody [EP1008Y] (ab52973)

Predicted band size: 45 kDa

false

Western blot - Anti-Aurora A antibody [EP1008Y] (AB52973)
  • WB

Unknown

Western blot - Anti-Aurora A antibody [EP1008Y] (AB52973)

All lanes:

Western blot - Anti-Aurora A antibody [EP1008Y] (ab52973) at 1/50000 dilution

All lanes:

HepG2 (Human liver hepatocellular carcinoma cell line) cell lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size: 45 kDa

Observed band size: 46 kDa

false

  • Carrier free

    Anti-Aurora A antibody [EP1008Y] - BSA and Azide free

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-Aurora A antibody [EP1008Y]

  • 578 PE

    PE Anti-Aurora A antibody [EP1008Y]

  • 660 APC

    APC Anti-Aurora A antibody [EP1008Y]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Aurora A antibody [EP1008Y]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Aurora A antibody [EP1008Y]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Aurora A antibody [EP1008Y]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Aurora A antibody [EP1008Y]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EP1008Y

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IP, WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/250", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/50", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/50000", "WB-species-notes": "<p></p>" } } }

Product details

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Aurora A also known as Aurora kinase A is an important serine/threonine kinase with a protein mass of approximately 46 kDa. It is commonly found in various tissues but its expression is particularly high during mitosis in dividing cells. Aurora A operates primarily at the centrosomes where it is pivotal for processes such as centrosome maturation separation and the establishment of the mitotic spindle. The kinase activity of Aurora A is important for proper chromosome alignment and segregation. Scientists often use Aurora A as a marker in studies related to cell division and cancer.
Biological function summary

Aurora A plays key roles in the regulation of the cell cycle and mitosis. It functions as part of the Aurora mouse kinase complex associating with other proteins to ensure accurate chromosomal segregation and cytokinesis. Aurora A is involved in centrosome dynamics and interacts with proteins such as 35C1 aiding its localization to the correct cellular structures. The protein’s role in the cell cycle and mitotic checkpoints makes it a subject of interest for researchers examining cancer proliferation.

Pathways

Aurora A integrates into both the mitotic spindle assembly checkpoint and DNA damage repair pathways. Within these pathways Aurora A partners with proteins like APC (Anaphase Promoting Complex) to ensure timely progression through mitosis and safeguard genomic stability. The spindle assembly pathway ensures that spindle fibers correctly attach to chromosomes a process in which Aurora A proves instrumental. Its interaction with other kinases and regulatory molecules in these pathways highlights its regulatory importance in cell proliferation.

Research identifies Aurora A's association with oncological conditions such as breast and ovarian cancers. Overexpression or amplification of Aurora A correlates with tumor progression and poor prognosis as it can lead to chromosomal instability. In these diseases Aurora A activity is linked with dysregulated pathways involving proteins like p53 and BRCA1 which normally function in DNA damage response and repair. Targeted inhibition of Aurora A represents a promising avenue in cancer therapy as it might restore normal cell cycle control and reduce cancer cell viability.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression (PubMed : 11039908, PubMed : 12390251, PubMed : 17125279, PubMed : 17360485, PubMed : 18615013, PubMed : 26246606). Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis (PubMed : 14523000, PubMed : 26246606). Required for normal spindle positioning during mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex during metaphase (PubMed : 27335426). Required for initial activation of CDK1 at centrosomes (PubMed : 13678582, PubMed : 15128871). Phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2 (PubMed : 11551964, PubMed : 14702041, PubMed : 15128871, PubMed : 15147269, PubMed : 15987997, PubMed : 17604723, PubMed : 18056443, PubMed : 18615013). Regulates KIF2A tubulin depolymerase activity (PubMed : 19351716). Important for microtubule formation and/or stabilization (PubMed : 18056443). Required for normal axon formation (PubMed : 19812038). Plays a role in microtubule remodeling during neurite extension (PubMed : 19668197). Also acts as a key regulatory component of the p53/TP53 pathway, and particularly the checkpoint-response pathways critical for oncogenic transformation of cells, by phosphorylating and destabilizing p53/TP53 (PubMed : 14702041). Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) isoforms, to inhibit their activity (PubMed : 11551964). Inhibits cilia outgrowth (By similarity). Required for cilia disassembly via phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin (PubMed : 17604723, PubMed : 20643351). Regulates protein levels of the anti-apoptosis protein BIRC5 by suppressing the expression of the SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through the phosphorylation of the transcription factor FOXP1 (PubMed : 28218735).
See full target information AURKA

Publications (28)

Recent publications for all applications. Explore the full list and refine your search

PloS one 19:e0313939 PubMed39585848

2024

Validation of the biological function and prognostic significance of AURKA in neuroblastoma.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Chu

Journal of medicinal chemistry 67:15521-15536 PubMed39190548

2024

Selective Aurora A-TPX2 Interaction Inhibitors Have Efficacy as Targeted Antimitotic Agents.

Applications

Unspecified application

Species

Unspecified reactive species

Simon R Stockwell,Duncan E Scott,Gerhard Fischer,Estrella Guarino,Timothy P C Rooney,Tzu-Shean Feng,Tommaso Moschetti,Rajavel Srinivasan,Esther Alza,Alice Asteian,Claudio Dagostin,Anna Alcaide,Mathieu Rocaboy,Beata Blaszczyk,Alicia Higueruelo,Xuelu Wang,Maxim Rossmann,Trevor R Perrior,Tom L Blundell,David R Spring,Grahame McKenzie,Chris Abell,John Skidmore,Ashok R Venkitaraman,Marko Hyvönen

Theranostics 14:3909-3926 PubMed38994036

2024

Caspase-mediated AURKA cleavage at Asp is essential for paclitaxel to elicit cell apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoting Chen,Shujuan Du,Yulin Zhang,Ke Peng,Lina Liu,Ting Wang,Hao Zhang,Shen Cai,Caixia Zhu,Youhai Li,Wen Tuo,Yuyan Wang,Fang Wei,Qiliang Cai

Frontiers in oncology 14:1379420 PubMed38903715

2024

Predictive and prognostic value of aurora kinase A combined with tumor-infiltrating lymphocytes in medullary thyroid carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Zhongyu Wang,Fengli Guo,Guiming Fu,Zewei Zhao,Ning Kang,Xiukun Hou,Xiangqian Zheng

Heliyon 10:e27959 PubMed38655290

2024

AURKA promotes renal cell carcinoma progression via regulation of CCNB1 transcription.

Applications

Unspecified application

Species

Unspecified reactive species

Jiling Wen,Xuechun Wang,Guosheng Yang,Junhua Zheng

British journal of cancer 130:1841-1854 PubMed38553589

2024

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoxiao Hu,Yilu Zhou,Charlotte Hill,Kai Chen,Cheng Cheng,Xiaowei Liu,Peiwen Duan,Yaoyao Gu,Yeming Wu,Rob M Ewing,Zhongrong Li,Zhixiang Wu,Yihua Wang

Translational cancer research 13:173-190 PubMed38410201

2024

Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.

Applications

Unspecified application

Species

Unspecified reactive species

Hai-Kuo Wang,Xuan-Hao Xu,Si-Ming Wang,He-Yun Zhang

Cell death discovery 9:316 PubMed37773181

2023

LncRNA TIALD contributes to hepatocellular carcinoma metastasis via inducing AURKA lysosomal degradation.

Applications

Unspecified application

Species

Unspecified reactive species

Yingchao Wang,Yue Zhong,Xiaoyuan Zheng,Niangmei Cheng,Yong Yang,Ye Yang,Fei Wang,Qiuyu Zhuang,Yao Huang,Wuhua Guo,Naishun Liao,Xiaoyu Yang,Bixing Zhao,Xiaolong Liu

Cell death & disease 14:386 PubMed37386026

2023

SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.

Applications

Unspecified application

Species

Unspecified reactive species

Yi Zeng,Gang Ma,Fenglin Cai,Pengliang Wang,Han Liang,Rupeng Zhang,Jingyu Deng,Yong Liu

Cell death & disease 14:224 PubMed36990998

2023

Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis.

Applications

Unspecified application

Species

Unspecified reactive species

Zhi Jingtai,Hu Linfei,Qian Yuyang,Kang Ning,Yun Xinwei,Wang Xin,Ruan Xianhui,Huang Dongmei,Yang Weiwei,Meng Xiangrui,Zhu Tianze,Wang Wei,Zheng Xiangqian
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com